PUBLIC POLICY
ASM Policy efforts focus on communicating the importance of the microbial science to Congress, Federal Agencies and the Public.
Wednesday, 22 March 2017 12:30

Public Policy Brief - March 22, 2017

Thursday, 16 March 2017 10:06

Public Policy Brief - March 16, 2017

Wednesday, 15 March 2017 13:13

Public Policy Brief - March 15, 2017

ASM and the Pan American Society of Clinical Virology (PASCV) drafted a letter expressing concerns about the turnaround time for results in the Zika plaque reduction neutralizing test (PRNT) currently available and suggested some solutions.   

Thursday, 09 March 2017 10:41

Public Policy Brief - March 9, 2017

The ASM signed onto a letter to Mr. António Guterres, United Nations Secretary-General and Dr. Margaret Chan, World Health Organization Director-General regarding the progress since the political declaration of the high level meeting on antimicrobial resistance (AMR) in the United Nations (UN) General Assembly in September 2016.

The ASM signed on to a letter to President Trump regarding the essential role of the federal public health and biomedical research workforce as long-term policy regarding federal hiring is considered.

The ASM submitted funding recommendations for the National Institutes of Health for FY 2018 to Congress. 

The ASM submitted funding recommendations for the Centers for Disease Control and Prevention for FY 2018 to Congress. 

Thursday, 23 February 2017 12:24

Public Policy Brief - February 23, 2017

The ASM sent a letter to Senator Lamar Alexander (R-TN), chair and Senator Patty Murray (D-WA), ranking member of the Senate's health committee and Representative Greg Walden (R-OR), chair and Representative Frank Pallone Jr. (D-NJ), ranking member of the House Energy & Commerce Committee, and Texas Reps. Michael Burgess (R) and Gene Green (D), chairman and ranking member of the subcommittee on health regarding their “Dear Colleague” letter to their colleagues highlighting the benefits of vaccines.

Wednesday, 22 February 2017 10:15

Public Policy Brief - February 22, 2017

Effective October 2016, the Centers for Disease Control and Prevention added Bacillus cereus biovar anthracis as a Tier 1 select agent to the list of select agents and toxins. Sentinel laboratories should continue using the existing ASM Sentinel Level Clinical Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases, Bacillus anthracis with new recommendations suggested here.  

Thursday, 09 February 2017 12:59

Coalition Letter Supporting Biomedical Research

The ASM signed onto a letter to President Trump and Congressional leadership, urging the completion of an FY 2017 spending package that includes $34.1 billion for the National Institutes of Health (NIH). The letter was signed by 260 patient, medical, scientific, academic, and research organizations.

Wednesday, 08 February 2017 14:45

Public Policy Daily Brief – February 8, 2017

Tuesday, 07 February 2017 13:54

Coalition Letter Supporting Vaccine Safety

The ASM joined over 350 organizations in a letter to President Donald Trump expressing support for the safety of vaccines. 

Wednesday, 01 February 2017 11:25

Public Policy Daily Brief - February 1, 2017

Page 1 of 2

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH